| Literature DB >> 25744720 |
Shuangshuang Zhong1, Huijing Yin1, Yueling Liao1, Feng Yao2, Qi Li3, Jie Zhang4, Huike Jiao5, Yongxu Zhao5, Dongliang Xu6, Shuli Liu7, Hongyong Song1, Yong Gao8, Jingyi Liu9, Lina Ma6, Zhi Pang6, Ruixu Yang6, Chengyi Ding6, Beibei Sun4, Xiaofeng Lin10, Xiaofeng Ye10, Wenzheng Guo1, Baohui Han4, Binhua P Zhou11, Y Eugene Chin12, Jiong Deng13.
Abstract
GPRC5A is a G-protein-coupled receptor expressed in lung tissue but repressed in most human lung cancers. Studies in Gprc5a(-/-) mice have established its role as a tumor-suppressor function in this setting, but the basis for its role has been obscure. Here, we report that GPRC5A functions as a negative modulator of EGFR signaling. Mouse tracheal epithelial cells (MTEC) from Gprc5a(-/-) mice exhibited a relative increase in EGFR and downstream STAT3 signaling, whereas GPRC5A expression inhibited EGFR and STAT3 signaling. GPRC5A physically interacted with EGFR through its transmembrane domain, which was required for its EGFR inhibitory activity. Gprc5a(-/-) MTEC were much more susceptible to EGFR inhibitors than wild-type MTEC, suggesting their dependence on EGFR signaling for proliferation and survival. Dysregulated EGFR and STAT3 were identified in the normal epithelia of small and terminal bronchioles as well as tumors of Gprc5a(-/-) mouse lungs. Moreover, in these lungs EGFR inhibitor treatment inhibited EGFR and STAT3 activation along with cell proliferation. Finally, overexpression of ectopic GPRC5A in human non-small cell lung carcinoma cells inhibited both EGF-induced and constitutively activated EGFR signaling. Taken together, our results show how GPRC5A deficiency leads to dysregulated EGFR and STAT3 signaling and lung tumorigenesis. Cancer Res; 75(9); 1801-14. ©2015 AACR. ©2015 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25744720 DOI: 10.1158/0008-5472.CAN-14-2005
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701